Mobile Menu

Beyond companion diagnostics – what next for ctDNA liquid biopsy in the NHS?

When: March 31, 2021 Time: 3:00 pm

Liquid biopsy has the promise to revolutionise cancer care and treatment, allowing the detection of rare cell types with a non-invasive test. It has applications within early cancer detection, ongoing monitoring and the gathering of information where surgical biopsy isn’t an option. One of the biomarkers detected from these tests is circulating cell-free DNA (ctDNA).

The recent Genome UK report, from the UK Government, highlights the latest vision – “to create the most advanced genomic healthcare ecosystem” – with liquid biopsy playing a clear role in this. But how is this technology being used in the NHS?

In this session from the Festival of Genomics and Biodata 2021, you will hear from Mark Kroese, (Director, PHG Foundation), Rachel Butler (Director, South West Genomic Laboratory Hub), Anca Oniscu (Clinical Lead Molecular Pathology, Royal Infirmary of Edinburgh), Nitzan Rosenfeld (Senior Group Leader, Cancer Research UK Cambridge Institute) and Laura Blackburn (Head of Science, PHG Foundation).

What will you take away from this webinar

  • The progress so far on developing clinical applications for liquid biopsy
  • How liquid biopsy is used in the early detection and management of cancer
  • How liquid biopsy could be implemented in the NHS
  • What are the policy issues surrounding this?

This webinar has been made possible with the kind support of our partner, The PHG Foundation.

Register for the webinar


Mark Kroese Mark Kroese, Director, PHG Foundation

Rachel Butler Rachel Butler, Director, South West Genomic Laboratory Hub

Anca Oniscu Anca Oniscu, Clinical Lead, Molecular Pathology, Royal Infirmary of Edinburgh

Nitzan Rosenfeld Nitzan Rosenfeld, Senior Group Leader, Cancer Research UK Cambridge Institute

Laura Blackburn Laura Blackburn , Head of Science, PHG Foundation

More on these topics

Healthcare / Liquid Biopsy / NHS

Article Search